Oxidation-Sensitive Wet Granulation of Promethazine Hydrochloride Tablet Cores

In companion-animal oral solid dosage manufacturing, promethazine hydrochloride is formulated into compressed tablets at typical active loadings of 12.5 mg to 25 mg per unit, corresponding to approximately 10–30% w/w in a 100–200 mg tablet core. The granulation process must reconcile the API’s aqueous solubility with the phenothiazine nucleus’s susceptibility to autoxidation; therefore low-moisture wet granulation is preferred over high-shear aqueous granulation when high-shear granulator torque identifies endpoint LOD above 3.0%. A representative production sequence uses a top-drive high-shear granulator operating at impeller 250–350 rpm and chopper 1,500 rpm, with a binder solution of povidone K30 at 5% w/w in purified water, sprayed at 20–30 g/min/kg powder load. Granules are dried in a fluid-bed dryer to a loss-on-drying value not more than 2.0% at inlet air temperature 45–50°C; inlet air above 55°C is avoided because oxidative discoloration and sulfoxide impurity growth accelerate near that threshold. Dried granules are milled through an 850 µm square-mesh screen. The lubricated blend includes croscarmellose sodium 2.0% w/w, microcrystalline cellulose, lactose monohydrate, and magnesium stearate 0.75% w/w, with total mixing after magnesium stearate limited to 3–5 min to avoid overlubrication. Compression on a rotary tablet press at 25–40 rpm targets a hardness of 5–8 kp and friability not exceeding 1.0% under USP <1216>. Uniformity of dosage units is assessed by USP <905> with an acceptance value not more than 15.0; dissolution uses USP <711> with apparatus 2 and a validated pharmacopeial dissolution medium. Elemental impurity control follows ICH Q3D oral permitted daily exposure limits. Because promethazine hydrochloride is light-sensitive, an opaque titanium dioxide-containing film coating is applied to 3–4% w/w weight gain. The terminal finished product is an immediate-release veterinary tablet for non-food companion animals, packaged in amber HDPE bottles with desiccant canisters.

What Limits Terminal Sterilization of Promethazine Hydrochloride Injection in Small-Animal Parenteral Use?

Promethazine hydrochloride injection for veterinary parenteral administration is conventionally prepared as 25 mg/mL or 50 mg/mL aqueous solution, representing 2.5% w/v and 5.0% w/v active content respectively. The finished solution is buffered to pH 4.0–5.5 with acetic acid/sodium acetate; multidose containers require a preservative system, commonly phenol at 0.5% w/v, while single-dose ampoules omit preservatives. The critical process conflict is the phenothiazine oxidation pathway: at terminal steam sterilization temperatures of 121°C for 15 min, promethazine sulfoxide formation accelerates unless dissolved oxygen is reduced below 0.5 ppm by nitrogen sparging or vacuum degassing, and a sacrificial antioxidant such as sodium metabisulfite at 0.1% w/v is incorporated. Aseptic filtration through a 0.22 µm polyvinylidene fluoride membrane is therefore preferred over saturated-steam terminal sterilization; where terminal sterilization is unavoidable, the formulation headspace residual oxygen is maintained below 0.5% and the cycle is validated with a lethality F₀ of 8–12 min. Vessel contact surfaces should be 316L stainless steel or borosilicate glass, because trace iron and copper ions catalyze phenothiazine degradation; the addition of disodium edetate at 0.005–0.01% w/v chelates transition metals. Particulate matter is controlled by USP <788> light obscuration testing of the final filled product; bacterial endotoxins are controlled under USP <85> using the limit K/M where K is 5 EU/kg for veterinary parenteral products and M is the maximum dose administered per kilogram per hour. Preservative efficacy in multidose vials is tested under USP <51>. Sterility assurance follows 21 CFR 211 aseptic processing requirements and USP <1> injectable product criteria. Published stability data for promethazine hydrochloride veterinary injectable configurations are limited; therefore oxidation kinetic studies under ICH Q1A(R2) photostability and accelerated conditions are required to establish a product-specific expiry. The terminal finished product is a sterile injectable solution in amber glass ampoules or vials intended for small-animal antiemetic and antihistaminic use under veterinary supervision.

Hard gelatin capsule manufacture of promethazine hydrochloride for non-food companion animals departs from aqueous granulation because residual moisture above 1.5% in capsule fill can induce gelatin cross-linking and phenothiazine oxidation. Capsules are produced by dry granulation of a blend containing promethazine hydrochloride at 25 mg per 100 mg fill weight, equivalent to 25% w/w, with lactose monohydrate 200 M, microcrystalline cellulose 102, and croscarmellose sodium 2.0% w/w. The dry blend is compacted on a roller compactor at roll pressure 20–40 kN, gap 2–3 mm, and roll speed 3–5 rpm; compacted ribbons are milled to granules with particle size 250–850 µm, and the granulation is blended with colloidal silicon dioxide 0.5% w/w as glidant and magnesium stearate 0.75% w/w as lubricant. Bulk density of the final blend is maintained between 0.45 g/mL and 0.65 g/mL, and Carr index below 20, to avoid weight variation on high-speed capsule filling equipment. Compliance for release testing uses USP <905> uniformity of dosage units and USP <711> dissolution; capsule disintegration follows USP <701> with water at 37±2°C, and moisture content is controlled under USP <921> Method Ia with a specification not more than 1.5% for finished capsules. Residual solvent limits are taken from ICH Q3C Class 3 solvents when solvent-based film coating of granules is used. The terminal finished product is a hard gelatin capsule, usually size 2 or 3, for oral administration to non-food companion animals.

Where dose titration in feline or small-breed canine practice demands increments below compressed tablet strengths, promethazine hydrochloride is prepared as a preserved oral solution at 1.25 mg/mL to 5.0 mg/mL, depending on the prescribing convention in the target jurisdiction. The manufacturing sequence dissolves promethazine hydrochloride in purified water or a sorbitol 70% non-crystallizing solution under nitrogen sparging; sodium citrate/citric acid buffer adjusts the pH to 4.0–5.5, and a preservative combination of methylparaben 0.1% w/v and propylparaben 0.02% w/v is added at 60–70°C before cooling. Sodium metabisulfite 0.1% w/v acts as the antioxidant, and disodium edetate 0.005% w/v chelates trace metal ions that otherwise catalyze sulfoxide formation. The solution is passed through a 75 µm stainless steel screen, then clarified through a 1.2 µm prefilter and 0.45 µm membrane filter; dissolved oxygen is maintained below 0.5 ppm throughout filling. Non-sterile compounding compliance is assessed under USP <795> for beyond-use dating and USP <1112> for microbial risk classification, while microbial enumeration and specified organisms are tested by USP <61> and USP <62>. Because promethazine hydrochloride is light-sensitive, the finished product is filled into amber polyethylene terephthalate bottles with child-resistant closures and stored below 25°C at relative humidity not exceeding 60%. The terminal finished product is an oral solution for acute and chronic antihistamine therapy in non-food companion animal patients, with package-specific beyond-use dating assigned from a bracketed stability protocol.

Powder-to-Suspension Intermediates and the Moisture Barrier Problem

Promethazine hydrochloride powders and granules are supplied to veterinary pharmacies as non-sterile intermediates for extemporaneous reconstitution into oral suspensions or capsules. Typical active content in such intermediates is 10% w/w, though dilution for low-dose feline use may reduce the concentration to 5% w/w; the remaining matrix is composed of lactose monohydrate, microcrystalline cellulose, and a hydrophilic polymer such as xanthan gum at 0.5–1.0% w/w for suspension viscosity build. The production process uses geometric dilution in a V-blender at 60% nominal capacity, blend time 15–20 min at 10–15 rpm, followed by dry granulation through an 850 µm screen; final moisture content is controlled below 1.5% by USP <921> Method Ia, and powder flow is characterized by USP <1174> compressibility index and Hausner ratio with limits not more than 20% and 1.25, respectively. The moisture barrier problem arises when polyvinylpyrrolidone-based binders are incorporated into the powder before storage: at relative humidity above 60%, the binder undergoes a glassy-to-rubbery transition that raises the cohesion index and causes segregation of the active fraction during subsequent pharmacy transfer. Packaging therefore uses double polyethylene bags inside aluminum-laminated pouches with desiccant, and the storage specification is 15–25°C at ≤40% relative humidity. Compliance for non-sterile compounding intermediates is anchored to USP <795> and current good manufacturing practices for veterinary active pharmaceutical ingredients under EudraLex Volume 4 Part II; residual solvents are controlled by VICH GL18 and elemental impurities by ICH Q3D. The terminal finished product is a pharmacy-compounded oral suspension or capsule prepared from the powder intermediate for non-food companion animals.

When Promethazine Hydrochloride Premix Is Intended for Non-Food Companion Species, Carrier Particle Size Governs Blend Uniformity

A premix containing promethazine hydrochloride for subsequent dilution by veterinary pharmacy or licensed manufacturer is prepared at 2–10% w/w active on a directly compressible carrier such as lactose monohydrate 200 M or microcrystalline cellulose 101. Carrier particle size governs blend uniformity because fine active particles below 75 µm adhere preferentially to coarse carrier particles in the 150–250 µm range; this adhesion reduces segregation but can create dead zones in low-shear mixers if the carrier moisture exceeds 0.5%. The manufacturing process screens promethazine hydrochloride through a 500 µm sieve, preblends with the carrier at a 1:5 ratio for 3 min, then discharges into a ribbon blender running at 15 rpm for 10–15 min; high-shear blending is avoided because localized frictional heating above 40°C accelerates oxidation of the phenothiazine nucleus. Blend uniformity is tested under USP <905> powder blend sampling with acceptance value not more than 15.0 at the 10× scale of the intended pharmacy dilution. The finished premix is intended for incorporation into oral pastes, oil-based top dressings, or reconstitutable suspensions for non-food companion species; use in food-producing animals is outside the permitted label, and the premix must be marked with the warning statement required by the target jurisdiction. Compliance references include USP <795> for extemporaneous compounding, ICH Q3C residual solvent classes, and VICH GL18 for residual solvents in veterinary medicinal products. The terminal finished product is a non-sterile premix for dilution into companion animal oral preparations, supplied in foil-lined fiber drums with desiccant and tamper-evident liners.